08 maj: Selskabernes forventninger - tirsdag den 8 maj
08 maj: USA/aktier: Filmen The Avengers løftede Walt Disney
08-05-2012 07:01:00

Actelion presents its strategy for value creation

Relateret indhold

Actelion Pharmaceuticals Ltd /

Actelion presents its strategy for value creation

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2012 - Actelion (SIX: ATLN) will today outline the company's three key strategic elements for value creation at an investor event in London.


Expanding Actelion's leadership in the PAH market

Actelion is well positioned to expand its leadership in the PAH market following the recent successful conclusion of the landmark SERAPHIN morbidity/mortality study with macitentan in patients suffering from pulmonary arterial hypertension.  

Actelion's new product pipeline in PAH also includes selexipag, a novel prostacyclin-IP receptor agonist, currently evaluated in a Phase III morbidity/mortality study.


Refocusing R&D on specialty areas

Actelion will refocus its future R&D activities towards specialty markets. Actelion's current clinical pipeline in immunomodulation and antibiotics provides the company with an opportunity to build a second specialty business franchise, thus accelerating revenue growth and diversifying Actelion's risk profile.


Accelerating cost saving initiatives

Refocusing of Actelion's research and development efforts into specialty areas is expected to result in lower and more targeted R&D spending, as well as lower overhead costs. This is in addition to Actelion's ongoing cost saving program.

Financial Outlook: The execution of Actelion's strategy for value creation is expected - unforeseen events excluded - to produce stable core earnings in 2013 (in local currencies), followed by a return to growth in 2014 and accelerating to double digit growth in 2015.

Jean-Paul Clozel, MD and Chief Executive Officer of Actelion commented: "I am committed to value creation for our shareholders. After the promising macitentan results, Actelion will more than ever continue its effort in the PAH market. The strength of our pipeline and our renewed efforts to optimize profitability will produce a bright future for Actelion."

The complete company update presentation is scheduled in London on Tuesday, 08 May 2012, at 10.00 CEST/ 09.00 BST/ 4.00 a.m. EST and is also made available on the company website, www.actelion.com.


Company Update Conference Call / Audiocast details:


08 May 2012        10.00 hrs - 11.30 hrs          Basel (CEST)

                                09.00 hrs - 10.30 hrs          UK (BST)

                                04.00 a.m. - 5.30 a.m.       US (EST)

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial:                        Europe: +41 (0)44 580 00 74

                                UK:         +44 (0)203 367 94 53

                                US:         +1 866 907 59 23

Participant's mode:


Audiocast Access:

Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.

If you experience any access problems go directly to the URL: http://view-w.tv/p/120-121-11206/en

Participant's mode:

Listen only

Audiocast Replay:

The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.

Actelion Ltd.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).

For further information please contact:

Roland Haefeli

Senior Vice President, Head of Investor Relations & Public Affairs

Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil

+41 61 565 62 62

+1 650 624 69 36


The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates",  "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks",  "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions.  Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Press Release PDF

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE


Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo mister tronen som tungeste aktie i C20 Cap

27-03-2017 09:40:18
Novo Nordisk har ikke længere den største indflydelse på udviklingen i det toneangivende danske aktieindeks, C20 Cap.Medicinalgiganten fra Bagsværd er faldet ned på andenpladsen i vægtningen i indekset trods en markedsværdi, der fortsat er klart den højeste blandt de børsnoterede danske selskaber.Danske Bank er den nye på topplaceringen med en vægt på 14,5 pct., mens Novo-aktien er faldet til 12,9..

Vind/Siemens: Hele vindindustrien vil få glæde af skatterabat

27-03-2017 06:34:14
Som led i et nyt vækstudspil vil Socialdemokratiet indføre en skatterabat på 130 procent for udgifter til forskning og udvikling.Sådan en aftale er efterspurgt blandt flere virksomheder i Danmark. En af dem er Siemens Windpower:- Det vil være en vigtig aftale, som hele vindindustrien vil få glæde af, da det er en industri, der er drevet af innovation og fornyelse.- Og sådan en aftale vil skabe de ..

Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY

24-03-2017 13:31:36
Udvalget for humanmedicinske lægemidler (CHMP) ved Det Europæiske Lægemiddelsagentur (EMA) har tildelt Novo Nordisks Refixia en positiv udtalelse og anbefaler en markedsføringstilladelse.Det skriver Novo Nordisk i en fondsbørsmeddelelse.CHMP anbefaler en markedsføringstilladelse til Refixia til unge og voksne med hæmofili B. Til grund for anbefalingen ligger resultater fra udviklingsprogrammet par..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
Novo mister tronen som tungeste aktie i C20 Cap
Aktier/tendens: Trump-forlis kan sende aktier i minus
Vind/Siemens: Hele vindindustrien vil få glæde af skatterabat
Mærsk/Seaintel: Ratesucces 1. april er særligt vigtig
G4S/RBC: Løfter kursmålet med 13 pct.

Relaterede aktiekurser

Actelion N 273,50 -0,3% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
27. marts 2017 12:43:57
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB7 - 2017-03-27 12:43:57 - 2017-03-27 12:43:57 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her